Homology Medicines Inc
For the period ended Dec 31, 2023. Filed Mar 13, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 13, 2024
QTTB$9.25+4.5%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| For the Year ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Collaboration revenue | $1,156 | $3,208 |
| Operating expenses: | ||
| Research and development | 62,002 | 98,351 |
| General and administrative | 31,256 | 38,138 |
| Restructuring and other charges | 9,327 | — |
| Total operating expenses | 102,585 | 136,489 |
| Loss from operations | (101,429) | (133,281) |
| Other income: | ||
| Gain on sale of business | — | 131,249 |
| Gain on lease termination | 8,767 | — |
| Interest income | 5,582 | 3,230 |
| Total other income | 14,349 | 134,479 |
| Income (loss) before income taxes | (87,080) | 1,198 |
| Provision for income taxes | — | (715) |
| Loss from equity method investment | (25,881) | (5,488) |
| Net loss | $(112,961) | $(5,005) |
| Net loss per share-basic and diluted | $(1.95) | $(0.09) |
| Weighted-average common shares outstanding-basic and diluted | 57,834,819 | 57,399,762 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.